← Leaderboards
Andras A. Heczey
Baylor College Of Medicine
$2,725,684
Attributed
$2,961,063
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,961,063 · 2
By mechanism
R01$2,490,304 · 1
R21$470,759 · 1
Top collaborators
- Laising Lewis Yen1 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Pavel Sumazin$795,451
- Anil Kumar Jaiswal$15,017,310
- C P Steuber$1,047,551
- Jochen Meyer$1,061,578
- Dolores Lopez-Terrada$982,354
Others in their field
Other Rising Stars on “Phenotype”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Michelle Rives · Baylor College Of Medicine$20,650,593
- Suma Babu · Massachusetts General Hospital$20,303,231
- Sabrina Paganoni · Massachusetts General Hospital$20,303,231
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
Research focus
PhenotypeSignal TransductionHematologic NeoplasmsPeripheral BloodProgramsSafetyChimeric Antigen Receptor T CellsGpc3 GeneIn VivoNeoplastic CellAntigensPrimary Carcinoma Of The Liver CellsCytokinePropertyCellsAntitumor ResponseEvaluationExhaustionInsightInterleukin-15Malignant NeoplasmsMediatingChimeric Antigen ReceptorSolid
Grant awards (5)
IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors$631,007
R01 · FY2025 · CA · contact PI
pA-regulator controlled, JMJD6 reprogrammed GPC3-CAR T cells for patients with hepatocellular carcinoma$470,759
R21 · FY2025 · CA · contact PI
IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors$601,989
R01 · FY2024 · CA · contact PI
IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors$622,304
R01 · FY2023 · CA · contact PI
IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors$635,004
R01 · FY2022 · CA · contact PI